SOFT 2004 Meeting Abstracts - Society of Forensic Toxicologists

A19
PERFORMANCE OF ASSAYS FOR THERAPEUTIC DRUG MONITORING AND URINE
DRUGS-OF-ABUSE SCREENING ON A CONSOLIDATED WORKSTATION
H. Luthet, I. Domke 2 , S. 10rdan·· J, M. Oellerich I, W. Stockmann 2
IGeorg-August-Universitaet, Goettingen, Germany, 2Roche Diagnostics GmbH, Mannheim, Germany,
JRoche Diagnotics Corp., Indianapolis, USA
Introduction: The study objective was the assessment of performance of nine Therapeutic Drug Monitoring
(TOM) assays and nine Drugs-of-Abuse assays (OAT) when processed in combination with simulated
routine workload on Modular Analytics P (Roche Diagnostics).
Methods: All TOM and OAT assays involve the kinetic interaction of microparticles in solution (KIMS)
except one enzymatic method. The study design comprises imprecision in simulated routine runs. The
experiment tests for potential systematic or random errors by comparing the imprecision of reference results
(standard batch) with results from samples run in a pattern simulating routine sampling. The study was
supported by a program for computer aided evaluation (CAEv).
Results: Within-run CVs of the reference runs ranged from 2 to 5 % for the majority of TOM
(Acetaminophen, Amikacin, Carbamazepine, Digitoxin, Gentamicin, Lidocaine, Phenobarbital, Phenytoin)
and OAT assays (Barbiturates, Cannabinoids, Cocaine Metabolite, Methadone, Opiates, Phencyclidine,
Propoxyphene). CVs up to 7 % were obtained for Digoxin, Amphetamines, and Benzodiazepines. Routine
simulation resulted in slightly increased CVs of maximal 2 %. This is in agreement with experience from
previous routine simulation studies.
Conclusion: With these results we conclude that no relevant reagent interactions occur on Modular Anaiytics
P when using it as a consolidated workstation for TOM, OAT, serum proteins and general chemistry assays.
Keywords: Therapeutic Drug Monitoring, Drugs-of-Abuse-Screening, Consolidated Workstation
Page 133